View Item 

Show simple item record

Decongestion in acute heart failure
dc.contributor.authorMentz, Robert J.en_US
dc.contributor.authorKjeldsen, Kelden_US
dc.contributor.authorRossi, Gian Paoloen_US
dc.contributor.authorVoors, Adriaan A.en_US
dc.contributor.authorCleland, John G.F.en_US
dc.contributor.authorAnker, Stefan D.en_US
dc.contributor.authorGheorghiade, Mihaien_US
dc.contributor.authorFiuzat, Monaen_US
dc.contributor.authorRossignol, Patricken_US
dc.contributor.authorZannad, Faiezen_US
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorO'Connor, Christopheren_US
dc.contributor.authorFelker, G. Michaelen_US
dc.date.accessioned2014-05-23T15:59:24Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-05-23T15:59:24Z
dc.date.issued2014-05en_US
dc.identifier.citationMentz, Robert J.; Kjeldsen, Keld; Rossi, Gian Paolo; Voors, Adriaan A.; Cleland, John G.F.; Anker, Stefan D.; Gheorghiade, Mihai; Fiuzat, Mona; Rossignol, Patrick; Zannad, Faiez; Pitt, Bertram; O'Connor, Christopher; Felker, G. Michael (2014). "Decongestion in acute heart failure." European Journal of Heart Failure 16(5): 471-482.en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106888
dc.publisherJohn Wiley & Sons, Ltden_US
dc.subject.otherStrategiesen_US
dc.subject.otherAcute Heart Failureen_US
dc.subject.otherVolume Overloaden_US
dc.subject.otherDecongestionen_US
dc.subject.otherOutcomesen_US
dc.titleDecongestion in acute heart failureen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106888/1/ejhf74.pdf
dc.identifier.doi10.1002/ejhf.74en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferencePublication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531 – 1540.en_US
dc.identifier.citedreferenceHockings BE, Cope GD, Clarke GM, Taylor RR. Randomized controlled trial of vasodilator therapy after myocardial infarction. Am J Cardiol 981; 48: 345 – 352.en_US
dc.identifier.citedreferenceCohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, Montero A, Cintron G, Clarke J, Hager D, Saunders R, Cobb F, Smith R, Loeb H, Settle H. Effect of short‐term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982; 306: 1129 – 1135.en_US
dc.identifier.citedreferenceColucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246 – 253.en_US
dc.identifier.citedreferenceO'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32 – 43.en_US
dc.identifier.citedreferenceGottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Hernandez AF. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure). J Am Coll Cardiol 2013; 62: 1177 – 1183.en_US
dc.identifier.citedreferenceGivertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin‐Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371 – 389.en_US
dc.identifier.citedreferenceCostanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675 – 683.en_US
dc.identifier.citedreferenceBradley SM, Levy WC, Veenstra DL. Cost–consequences of ultrafiltration for acute heart failure: a decision model analysis. Circ Cardiovasc Qual Outcomes 2009; 2: 566 – 573.en_US
dc.identifier.citedreferenceGoldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46: 1785 – 1791.en_US
dc.identifier.citedreferenceKonstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319 – 1331.en_US
dc.identifier.citedreferenceGheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332 – 1343.en_US
dc.identifier.citedreferencePang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009; 30: 2233 – 2240.en_US
dc.identifier.citedreferenceHauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013; 19: 390 – 397.en_US
dc.identifier.citedreferenceTorres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407 – 2418.en_US
dc.identifier.citedreferenceRossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post‐myocardial infarction are independent from its diuretic and potassium‐sparing effects. Insights from an EPHESUS (Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. JAMA 2011; 58: 1958 – 1966.en_US
dc.identifier.citedreferenceEffectiveness of spironolactone added to an angiotensin‐converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902 – 907.en_US
dc.identifier.citedreferenceBansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009; 2: 370 – 376.en_US
dc.identifier.citedreferenceFernandez‐Llama P, Ageloff S, Fernandez‐Varo G, Ros J, Wang X, Garra N, Esteva‐Font C, Ballarin J, Barcelo P, Arroyo V, Stokes JB, Knepper MA, Jimenez W. Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney Int 2005; 67: 622 – 630.en_US
dc.identifier.citedreferencePerez‐Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodes J. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin–aldosterone system. Gastroenterology. 1983; 84: 961 – 968.en_US
dc.identifier.citedreferencevan Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high‐dose loop diuretic and low‐dose angiotensin‐converting enzyme inhibitor. Am J Cardiol 1993; 71: 21a – 28a.en_US
dc.identifier.citedreferenceHensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 1991; 11: 441 – 446.en_US
dc.identifier.citedreferenceBraunwald E, Plauth WH Jr, Morrow AG. A method for the detection and quantification of impaired sodium excretion. Circulation 1965; 32: 223 – 231.en_US
dc.identifier.citedreferenceShchekochikhin D, Lindenfeld J, Schrier R. Increased spironolactone in advanced heart failure: effect of doses greater than 25 mg/day on plasma potassium concentration. Cardiorenal Med 2013; 3: 1 – 6.en_US
dc.identifier.citedreferenceZachariah D, Kalra PR. Managing patients with cardiorenal syndrome: time to look to the gut? Eur J Heart Fail 2012; 14: 870 – 872.en_US
dc.identifier.citedreferenceCostanzo MR, Heywood JT, Massie BM, Iwashita J, Henderson L, Mamatsashvili M, Sisakian H, Hayrapetyan H, Sager P, van Veldhuisen DJ, Albrecht D. A double‐blind, randomized, parallel, placebo‐controlled study examining the effect of cross‐linked polyelectrolyte in heart failure patients with chronic kidney disease. Eur J Heart Fail 2012; 14: 922 – 930.en_US
dc.identifier.citedreferenceConrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011; 301: R267 – R275.en_US
dc.identifier.citedreferenceTeerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M. Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial. Lancet 2013; 381: 29 – 39.en_US
dc.identifier.citedreferenceMetra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KFJ, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX‐AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196 – 206.en_US
dc.identifier.citedreferenceVoors A. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: main results of a randomized, placebo‐controlled, multi‐center study. HFSA Scientific Meeting; Late‐breaking clinical trials. 23 September 2013; Orlando, FL.en_US
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJ, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147 – e239.en_US
dc.identifier.citedreferenceFang J, Mensah GA, Croft JB, Keenan NL. Heart failure‐related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008; 52: 428 – 434.en_US
dc.identifier.citedreferenceMcMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez‐Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck‐Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803 – 869.en_US
dc.identifier.citedreferenceAdams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209 – 216.en_US
dc.identifier.citedreferenceCleland JG, Swedberg K, Follath F, Komajda M, Cohen‐Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442 – 463.en_US
dc.identifier.citedreferenceO'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT‐HF registry. J Card Fail 2005; 11: 200 – 205.en_US
dc.identifier.citedreferenceGheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006; 119 ( 12 Suppl 1 ): s3 – s10.en_US
dc.identifier.citedreferenceFonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4 ( Suppl 7 ): S21 – S30.en_US
dc.identifier.citedreferenceAmbrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 2013; 34: 835 – 843.en_US
dc.identifier.citedreferenceDrazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345: 574 – 581.en_US
dc.identifier.citedreferenceLucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000; 140: 840 – 847.en_US
dc.identifier.citedreferenceButler J, Kalogeropoulos A. Worsening heart failure hospitalization epidemic we do not know how to prevent and we do not know how to treat!. J Am Coll Cardiol 2008; 52: 435 – 437.en_US
dc.identifier.citedreferenceGheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010; 12: 423 – 433.en_US
dc.identifier.citedreferencePellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark AL, Cleland JG. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 2013; 6: 16 – 28.en_US
dc.identifier.citedreferenceSchiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003; 114: 625 – 630.en_US
dc.identifier.citedreferenceFallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 2011; 4: 669 – 675.en_US
dc.identifier.citedreferenceKoniari K, Parissis J, Paraskevaidis I, Anastasiou‐Nana M. Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches. Eur Heart J Acute Cardiovasc Care 2012; 1: 256 – 268.en_US
dc.identifier.citedreferenceColombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, LeJemtel TH, Bucciarelli L, Kebschull M, Papapanou P, Uriel N, Schmidt AM, Sabbah HN, Jorde UP. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J 2014; 35: 448 – 454.en_US
dc.identifier.citedreferenceCotter G, Metra M, Milo‐Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure—re‐distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008; 10: 165 – 169.en_US
dc.identifier.citedreferenceMilo‐Cotter O, Adams KF, O'Connor CM, Uriel N, Kaluski E, Felker GM, Weatherley B, Vered Z, Cotter G. Acute heart failure associated with high admission blood pressure—a distinct vascular disorder? Eur J Heart Fail 2007; 9: 178 – 183.en_US
dc.identifier.citedreferenceBalmain S, Padmanabhan N, Ferrell WR, Morton JJ, McMurray JJV. Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. Eur J Heart Fail 2007; 9: 865 – 871.en_US
dc.identifier.citedreferenceKawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003: 107714 – 720.en_US
dc.identifier.citedreferenceMilo O, Cotter G, Kaluski E, Brill A, Blatt A, Krakover R, Vered Z, Hershkoviz R. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol 2003; 92: 222 – 226.en_US
dc.identifier.citedreferenceColombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH. Endothelial cell activation in patients with decompensated heart failure. Circulation 2005; 111: 58 – 62.en_US
dc.identifier.citedreferenceMaxwell AP, Ong HY, Nicholls DP. Influence of progressive renal dysfunction in chronic heart failure. Eur J Heart Fail 2002; 4: 125 – 130.en_US
dc.identifier.citedreferenceFirth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988; 1: 1033 – 1035.en_US
dc.identifier.citedreferenceSchrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577 – 585.en_US
dc.identifier.citedreferenceNohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268 – 1274.en_US
dc.identifier.citedreferenceBart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296 – 2304.en_US
dc.identifier.citedreferenceLala A, Dunlay S, Vader J, Zakeri R, Ravichandran A, AbouEzzadine O, Khazanie P, McNulty S. The tides of congestion during and after hospitalization for acute decompensated heart failure. J Card Fail 2013; 19:Suppl S81.en_US
dc.identifier.citedreferenceLala A, Dunlay S, Vader J, Zakeri R, Ravichandran A, AbouEzzadine O, Khazanie P, McNulty S. A two‐symptom congestion score in relation to outcomes after discharge with acute decompensated heart failure. J Card Fail 2013; 19:Suppl S39.en_US
dc.identifier.citedreferenceStevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 884 – 888.en_US
dc.identifier.citedreferenceKociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, O'Connor CM, Felker GM. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 2013; 6: 240 – 245.en_US
dc.identifier.citedreferenceDi Somma S, De Berardinis B, Bongiovanni C, Marino R, Ferri E, Alfei B. Use of BNP and bioimpedance to drive therapy in heart failure patients. Congest Heart Fail 2010; 16 ( Suppl 1 ): S56 – S61.en_US
dc.identifier.citedreferenceMaisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen‐Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824 – 839.en_US
dc.identifier.citedreferencevan der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA. The predictive value of short‐term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 2013; 61: 1973 – 1981.en_US
dc.identifier.citedreferenceTestani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265 – 272.en_US
dc.identifier.citedreferenceTestani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WHW. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 2013; 62: 516 – 524.en_US
dc.identifier.citedreferenceFelker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 2012; 59: 2145 – 2153.en_US
dc.identifier.citedreferenceMurray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney WM, Brater DC. Open‐label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513 – 520.en_US
dc.identifier.citedreferenceCosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507 – 513.en_US
dc.identifier.citedreferenceMuller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. Eur J Heart Fail 2003; 5: 793 – 801.en_US
dc.identifier.citedreferenceDinicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012; 8: 707 – 728.en_US
dc.identifier.citedreferenceFelker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797 – 805.en_US
dc.identifier.citedreferenceKaissling B, Bachmann S, Kriz W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 1985; 248: F374 – F381.en_US
dc.identifier.citedreferenceEllison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132 – 143.en_US
dc.identifier.citedreferenceJentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide‐type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527 – 1534.en_US
dc.identifier.citedreferenceGoyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, Kosiborod M. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307: 157 – 164.en_US
dc.identifier.citedreferenceSchrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1 – 8.en_US
dc.identifier.citedreferenceDomanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705 – 708.en_US
dc.identifier.citedreferenceHasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064 – 1069.en_US
dc.identifier.citedreferenceMcCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301 – 1307.en_US
dc.identifier.citedreferenceFrancis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin‐Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724 – 1729.en_US
dc.identifier.citedreferenceFrancis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1 – 6.en_US
dc.identifier.citedreferenceHeywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422 – 430.en_US
dc.identifier.citedreferenceAronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 2010; 16: 541 – 547.en_US
dc.identifier.citedreferenceMullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589 – 596.en_US
dc.identifier.citedreferenceMetra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei CL. Is worsening renal function an ominous prognostic sign in patients with acute heart failure?: the role of congestion and its interaction with renal function. Circ Heart Fail 2012; 5: 54 – 62.en_US
dc.identifier.citedreferenceElkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high‐dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 2004; 93: 237 – 240.en_US
dc.identifier.citedreferenceElkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987; 76: 577 – 584.en_US
dc.identifier.citedreferenceMullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH. Sodium nitroprusside for advanced low‐output heart failure. J Am Coll Cardiol 2008; 52: 200 – 207.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf74.pdf
Size:
1.026MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.